13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Functional genomic Landscape of Human Breast Cancer drivers, vulnerabilities, and resistance

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Large-scale genomic studies have identified multiple somatic aberrations in breast cancer, including copy number alterations, and point mutations. Still, identifying causal variants and emergent vulnerabilities that arise as a consequence of genetic alterations remain major challenges. We performed whole genome shRNA “dropout screens” on 77 breast cancer cell lines. Using a hierarchical linear regression algorithm to score our screen results and integrate them with accompanying detailed genetic and proteomic information, we identify vulnerabilities in breast cancer, including candidate “drivers,” and reveal general functional genomic properties of cancer cells. Comparisons of gene essentiality with drug sensitivity data suggest potential resistance mechanisms, effects of existing anti-cancer drugs, and opportunities for combination therapy. Finally, we demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer, and PIK3CA mutations as a resistance determinant for BET-inhibitors.

          Related collections

          Author and article information

          Journal
          0413066
          2830
          Cell
          Cell
          Cell
          0092-8674
          1097-4172
          19 January 2016
          14 January 2016
          14 January 2017
          : 164
          : 0
          : 293-309
          Affiliations
          [1 ]Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, M5G 1L7
          [2 ]The Donnelly Centre, University of Toronto, Canada, M5S 3E1
          [3 ]Columbia University, New York, NY, USA, 10027
          [4 ]Department of Molecular Genetics, University of Toronto, Canada, M5S 3E1
          [5 ]Department of Medical Oncology, Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School, Boston, MA, USA, 02215
          [6 ]Department of System Biology, Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, the University of Texas MD Anderson Cancer Center, Houston, TX, USA, 77030
          [7 ]Laura and Isaac Perlmutter Cancer Centre, NYU-Langone Medical Center, NY, USA, 10016
          Author notes
          [+ ]Correspondence should be addressed to B.G.N ( Benjamin.neel@ 123456nyumc.org ) 522 First Avenue, Smilow 1201, 12 th Floor, New York, NY 10016. Phone: 212-263-3019; Fax: 212-263-9190
          [8]

          Present address: Ontario Institute for Cancer Research, Toronto, Canada, M5G 0A3

          [9]

          Present address: Laura and Isaac Perlmutter Cancer Centre, NYU-Langone Medical Center, NY, USA, 10016

          [10]

          Present address: National Research Council, Royalmount Ave, Montreal, Canada, H4P 2R2

          [*]

          Equal contributions

          Article
          PMC4724865 PMC4724865 4724865 nihpa744107
          10.1016/j.cell.2015.11.062
          4724865
          26771497
          75ffcf33-a2fa-4452-9b3f-17af904c512f
          History
          Categories
          Article

          Comments

          Comment on this article